Effective Treatment of COVID-19 Infection with Repurposed Drugs: Case Reports

Abraham M. Enyeji; Amit Arora; Harpal S. Mangat

Effective Treatment of COVID-19 Infection with Repurposed Drugs: Case Reports

Enyeji et al., Viral Immunology, doi:10.1089/vim.2024.0034, Aug 2024

41st treatment shown to reduce risk in May 2022, now with p = 0.0066 from 19 studies, recognized in 33 countries. Efficacy is variant dependent.

Lower risk for mortality, hospitalization, and cases.

No treatment is 100% effective. Protocols combine treatments.

6,300+ studies for 210+ treatments. c19early.org

Meta Analysis

Review of the successful treatment of COVID-19 using existing medications including HCQ, AZ, ivermectin, famotidine, monoclonal antibodies, and others. Authors note that the typical treatment of severe viral infections with multiple therapeutic agents has generally not been done in COVID-19 clinical trials, that different mechanisms of action from multiple treatments can minimize the emergence of drug-resistant SARS-CoV-2 strains, and that early treatment disrupts viral replication, avoids progression to cytokine storm, and is critical to avoid long-term complications.

Efficacy is variant dependent. In Vitro research suggests a lack of efficacy for omicron BA.2.75.2, BA.4.6, BQ.1.11, BA.5, BA.2.75, XBB2,3, XBB.1.53, ХВВ.1.9.13, XBB.1.9.3, XBB.1.5.24, XBB.1.16, XBB.2.9, BQ.1.1.45, CL.1, and CH.1.14.

Reviews covering tixagevimab/cilgavimab for COVID-19 include5-10.

Important missing comments or errors? Let us know.

Review covers ivermectin, HCQ, famotidine, bebtelovimab, tixagevimab/cilgavimab, and sotrovimab.

1. Planas et al., Resistance of Omicron subvariants BA.2.75.2, BA.4.6 and BQ.1.1 to neutralizing antibodies, bioRxiv, doi:10.1101/2022.11.17.516888.biorxiv.org, doi.org.

2. Haars et al., Prevalence of SARS-CoV-2 Omicron Sublineages and Spike Protein Mutations Conferring Resistance against Monoclonal Antibodies in a Swedish Cohort during 2022–2023, Microorganisms, doi:10.3390/microorganisms11102417.mdpi.com, doi.org.

3. Uraki et al., Antiviral efficacy against and replicative fitness of an XBB.1.9.1 clinical isolate, iScience, doi:10.1016/j.isci.2023.108147.sciencedirect.com, doi.org.

4. Pochtovyi et al., In Vitro Efficacy of Antivirals and Monoclonal Antibodies against SARS-CoV-2 Omicron Lineages XBB.1.9.1, XBB.1.9.3, XBB.1.5, XBB.1.16, XBB.2.4, BQ.1.1.45, CH.1.1, and CL.1, Vaccines, doi:10.3390/vaccines11101533.mdpi.com, doi.org.

5. Focosi et al., The Emergence of Escape Mutations in COVID-19 Following Anti-Spike Monoclonal Antibody Treatment: How Do We Tackle It?, Infection and Drug Resistance, doi:10.2147/IDR.S540928.dovepress.com, doi.org.

6. Vukovikj et al., Impact of SARS-CoV-2 variant mutations on susceptibility to monoclonal antibodies and antiviral drugs: a non-systematic review, April 2022 to October 2024, Eurosurveillance, doi:10.2807/1560-7917.ES.2025.30.10.2400252.eurosurveillance.org, doi.org.

7. Focosi (B), D., Monoclonal Antibody Therapies Against SARS-CoV-2: Promises and Realities, Current Topics in Microbiology and Immunology, doi:10.1007/82_2024_268.springer.com, doi.org.

8. Enyeji et al., Effective Treatment of COVID-19 Infection with Repurposed Drugs: Case Reports, Viral Immunology, doi:10.1089/vim.2024.0034.liebertpub.com, doi.org.

9. Focosi (C) et al., Analysis of SARS-CoV-2 mutations associated with resistance to therapeutic monoclonal antibodies that emerge after treatment, Drug Resistance Updates, doi:10.1016/j.drup.2023.100991.sciencedirect.com, doi.org.

10. Keam, S., Tixagevimab + Cilgavimab: First Approval, Drugs, doi:10.1007/s40265-022-01731-1.springer.com, doi.org.

Enyeji et al., 5 Aug 2024, peer-reviewed, 3 authors.

DOI record: { "DOI": "10.1089/vim.2024.0034", "ISSN": [ "0882-8245", "1557-8976" ], "URL": "http://dx.doi.org/10.1089/vim.2024.0034", "alternative-id": [ "10.1089/vim.2024.0034" ], "author": [ { "ORCID": "http://orcid.org/0000-0002-2653-8605", "affiliation": [ { "name": "Division of Community Medicine, Mercer University School of Medicine, Columbus, Georgia, 31901, USA." } ], "authenticated-orcid": false, "family": "Enyeji", "given": "Abraham M.", "sequence": "first" }, { "affiliation": [ { "name": "Georgetown University, Data Science and Analytics Washington, DC 20057, USA." } ], "family": "Arora", "given": "Amit", "sequence": "additional" }, { "affiliation": [ { "name": "Germantown Medical Health Center, Germantown, Maryland, 20876 USA." } ], "family": "Mangat", "given": "Harpal S.", "sequence": "additional" } ], "container-title": "Viral Immunology", "container-title-short": "Viral Immunology", "content-domain": { "crossmark-restriction": false, "domain": [] }, "created": { "date-parts": [ [ 2024, 8, 3 ] ], "date-time": "2024-08-03T11:03:52Z", "timestamp": 1722683032000 }, "deposited": { "date-parts": [ [ 2024, 8, 5 ] ], "date-time": "2024-08-05T14:00:56Z", "timestamp": 1722866456000 }, "indexed": { "date-parts": [ [ 2024, 8, 6 ] ], "date-time": "2024-08-06T00:25:30Z", "timestamp": 1722903930363 }, "is-referenced-by-count": 0, "issued": { "date-parts": [ [ 2024, 8, 5 ] ] }, "language": "en", "license": [ { "URL": "https://www.liebertpub.com/nv/resources-tools/text-and-data-mining-policy/121/", "content-version": "tdm", "delay-in-days": 0, "start": { "date-parts": [ [ 2024, 8, 5 ] ], "date-time": "2024-08-05T00:00:00Z", "timestamp": 1722816000000 } } ], "link": [ { "URL": "https://www.liebertpub.com/doi/full-xml/10.1089/vim.2024.0034", "content-type": "application/xml", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://www.liebertpub.com/doi/pdf/10.1089/vim.2024.0034", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking" } ], "member": "278", "original-title": [], "prefix": "10.1089", "published": { "date-parts": [ [ 2024, 8, 5 ] ] }, "published-online": { "date-parts": [ [ 2024, 8, 5 ] ] }, "publisher": "Mary Ann Liebert Inc", "reference": [ { "DOI": "10.1007/978-3-030-88863-3_14", "doi-asserted-by": "publisher", "key": "B1" }, { "DOI": "10.13016/i1wo-er4h", "doi-asserted-by": "publisher", "key": "B2" }, { "DOI": "10.1093/cid/ciac663", "doi-asserted-by": "publisher", "key": "B4" }, { "DOI": "10.1016/j.rce.2020.05.006", "doi-asserted-by": "publisher", "key": "B5" }, { "DOI": "10.1001/jamaoto.2020.1922", "doi-asserted-by": "publisher", "key": "B6" }, { "DOI": "10.7554/eLife.59177", "doi-asserted-by": "publisher", "key": "B7" }, { "DOI": "10.3390/ijms22115438", "doi-asserted-by": "publisher", "key": "B8" }, { "author": "Mangat HS", "first-page": "1088", "issue": "2", "journal-title": "Health Sci J", "key": "B9", "volume": "17", "year": "2023" }, { "DOI": "10.29121/granthaalayah.v8.i7.2020.678", "doi-asserted-by": "publisher", "key": "B10" }, { "DOI": "10.1016/j.jinf.2020.07.005", "doi-asserted-by": "publisher", "key": "B11" }, { "DOI": "10.1111/head.14006", "doi-asserted-by": "publisher", "key": "B12" }, { "DOI": "10.1016/j.envres.2020.109754", "doi-asserted-by": "publisher", "key": "B13" }, { "DOI": "10.34172/jrip.2020.19", "doi-asserted-by": "publisher", "key": "B14" }, { "DOI": "10.1126/SCIADV.ABD4049", "doi-asserted-by": "publisher", "key": "B15" } ], "reference-count": 14, "references-count": 14, "relation": {}, "resource": { "primary": { "URL": "https://www.liebertpub.com/doi/10.1089/vim.2024.0034" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [], "subtitle": [], "title": "Effective Treatment of COVID-19 Infection with Repurposed Drugs: Case Reports", "type": "journal-article" }